Progress of relationship between cytokines and treatment-related adverse events of immune checkpoint inhibitors in tumors and the clinical values
10.3760/cma.j.cn115355-20220106-00007
- VernacularTitle:细胞因子与肿瘤免疫检查点抑制剂治疗相关不良事件关系及临床价值的研究进展
- Author:
Lina YI
1
;
Yi YAO
;
Qibin SONG
Author Information
1. 武汉大学人民医院肿瘤中心，武汉 430060
- Keywords:
Cytokines;
Immune checkpoint inhibitors;
Tumor markers, biological;
Adverse event
- From:
Cancer Research and Clinic
2023;35(3):233-236
- CountryChina
- Language:Chinese
-
Abstract:
The use of immune checkpoint inhibitor (ICI) has significantly improved the efficacy of different types of malignancies, but the immune-related adverse event (irAE) callsed by ICI involves multiple organs and systems, affects the treatment, threatens the health of patients and even endangers their life. Therefore, it is necessary to select biomarkers to predict and monitor the occurrence of irAE, assist in the early diagnosis of high-risk patients, and guide individualized treatment. Recent studies have shown that some certain cytokines may be involved in the genesis and development of irAE. The article provides a review of studies related to cytokines and irAE to provide a reference for clinical prediction and monitoring of irAE.
